Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

628 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.
Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Recher C, Yoon SS, Maeda Y, Hosono N, Onozawa M, Kato T, Kim HJ, Hasabou N, Nuthethi R, Tiu R, Levis MJ. Perl AE, et al. Among authors: larson ra. Transplant Cell Ther. 2023 Apr;29(4):265.e1-265.e10. doi: 10.1016/j.jtct.2022.12.006. Epub 2022 Dec 13. Transplant Cell Ther. 2023. PMID: 36526260 Free PMC article. Clinical Trial.
Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors.
Roloff GW, Wen F, Ramsland A, Artz AS, Kosuri S, Stock W, Odenike O, Larson RA, Liu H, Godley LA, Thirman MJ, Patel AA, Daugherty CK, DuVall AS, Nawas MT, Dworkin E, Wool GD, Gurbuxani S, Fitzpatrick C, Segal JP, Wang P, Drazer MW. Roloff GW, et al. Among authors: larson ra. Haematologica. 2023 Aug 1;108(8):2234-2239. doi: 10.3324/haematol.2022.282148. Haematologica. 2023. PMID: 36655425 Free PMC article. No abstract available.
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Takahashi N, Kim I, Etienne G, Andorsky D, Issa GC, Larson RA, Bombaci F, Kapoor S, McCulloch T, Malek K, Yau L, Ifrah S, Hoch M, Cortes JE, Hughes TP; ASC4FIRST Investigators. Hochhaus A, et al. Among authors: larson ra. N Engl J Med. 2024 May 31. doi: 10.1056/NEJMoa2400858. Online ahead of print. N Engl J Med. 2024. PMID: 38820078
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation.
Roloff GW, Kosuri S, Nawas MT, DuVall AS, Patel AA, Riedell PA, Odenike O, Stock W, Larson RA, Bishop MR, Nunley E, Godley LA, Hathaway F, Del Gaudio D, Das S, Canham LE, Drazer MW. Roloff GW, et al. Among authors: larson ra. Haematologica. 2024 Apr 11. doi: 10.3324/haematol.2023.284584. Online ahead of print. Haematologica. 2024. PMID: 38618681 Free article.
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy.
Madero-Marroquin R, Dworkin E, Weiner H, Saygin C, Nawas MT, Drazer MW, DuVall AS, Kosuri S, Thirman MJ, Odenike O, Stock W, Larson RA, Patel AA. Madero-Marroquin R, et al. Among authors: larson ra. Leuk Lymphoma. 2024 Jun;65(6):864-867. doi: 10.1080/10428194.2024.2324991. Epub 2024 Mar 5. Leuk Lymphoma. 2024. PMID: 38441062 No abstract available.
628 results